Cart
sales@molnova.com
RGD-4C
CAS No. 332179-76-7
RGD-4C( ——— )
Catalog No. M41582 CAS No. 332179-76-7
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRGD-4C
-
NoteResearch use only, not for human use.
-
Brief DescriptionRGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models.
-
DescriptionRGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity.
-
In VitroRGD-4C (2.5, 5, 10 μg/mL) inhibits BAE cell proliferation by synthetic form modified with endostatin-derived peptides.
-
In VivoRGD-4C (9.11 mg/kg; injection; single dose) inhibits the growth of B16F10 mouse melanoma in vivo.Modified RGD-4C fused with the N-terminus of plant-derived single-chain ribosome inactivating protein saporin (SAP) (called RGD-SAP), (diluted in sodium chloride, 0.9%; i.v.; 200 μL; every 5 days, for 3 times) exerts anti-tumor activity in a model of muscle invasive bladder cancer. RGD-SAP in combination with mitomycin C, a chemotherapeutic drug, increases the survival of mice bearing orthotopic bladder cancer with no evidence of systemic toxicity.
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number332179-76-7
-
Formula Weight1145.29
-
Molecular FormulaC42H60N14O16S4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL (21.83 mM; ultraphonic; )
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ELOVL1-IN-2
ELOVL1-IN-2, a compound known as an inhibitor of the elongation of very long chain fatty acid 1 (ELOVL1) enzyme, exhibits a weak inhibitory effect on ELOVL1 (with an IC50 of 21 μM) and demonstrates moderate potency in a primary cellular assay conducted on HEK293 C26 cells (with an IC50 of 6.7 μM) .
-
Spirostan-3-ol
Spirostan-3-ol is a stereoisomer of Sarsasapogenin (S142505), a steroid glycoside isolated from plant materials. A saponin with with potential anti-tumor activity via apoptosis.
-
AVE 0991
AVE 0991, a nonpeptide analog of angiotensin-(1-7) [Ang-(1-7)], is an orally active Mas agonist with inhibitory effects on [125I]-Ang-(1-7) binding to bovine aortic endothelial cell membranes, and inhibits astrocyte-mediated neuroinflammation in Alzheimer's disease by enhancing autophagy.
